A randomized, placebo-controlled trial of the analgesic efficacy and safety of the p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain from …

T Ostenfeld, A Krishen, RY Lai, J Bullman… - The Clinical journal …, 2015 - journals.lww.com
Objectives: Preclinical studies have demonstrated involvement of p38 mitogen-activated
protein kinase signaling pathways in the development of persistent pain after peripheral
nerve injury. A double-blind, randomized, placebo-controlled study was undertaken to
evaluate the analgesic efficacy of losmapimod (GW856553), a novel p38α/β inhibitor, in
patients with chronic neuropathic pain due to lumbosacral radiculopathy. Materials and
Methods: A total of 144 patients with at least moderate baseline pain intensity (average daily …